Integrative Health Meets Clinical Science: OmniActive Launches Fenavari; Names Dr. Taz Bhatia, MD, As Women's Health Partner

Dr. Taz, Known For Bridging Eastern and Western Medicine In Her Clinical Practice, Lends Her Expertise As Fenavari Officially Launches Into The Natural Products Space

BRIDGEWATER, N.J. and MUMBAI, India, Oct. 13, 2026 /PRNewswire/ -- OmniActive Health Technologies (OmniActive), a global leader in the consumer wellness industry through innovative science and natural ingredients, today announced the official launch of Fenavari, its clinically studied botanical extract supporting women through their perimenopause and menopause journey—alongside the news that Dr. Taz Bhatia (Tasneem Bhatia), MD, has joined the brand as its women's health partner. The announcements arrive during World Menopause Month, a global observance dedicated to raising awareness of the menopause transition and the health solutions available to support it.

"Dr. Taz's philosophy sits at exactly the intersection Fenavari was built on—traditional, Eastern-rooted botanical medicine, validated by modern clinical science," said Keya Shah, Senior Director, Women's Health Category at OmniActive. "That's exactly why we partnered with her. She can translate that science into guidance other practitioners, formulators, and everyday women can actually use, making an intricate, often confusing category feel understandable."

Dr. Taz is a triple board-certified integrative and functional medicine physician and the founder of hol+, a holistic medicine company she founded in 2009 with clinics in Atlanta, New York City, and Los Angeles. Specializing in women's health, hormone health, and integrative medicine, her expertise aligns with Fenavari's approach of combining fenugreek and shatavari, two botanicals with centuries of traditional use, with new clinical validation.

"I've relied on both fenugreek and shatavari in my practice to help women through unique health concerns—whether during their maternal or menopause years—and I've seen firsthand what each can do," said Dr. Taz. "OmniActive's introduction of Fenavari brings two trusted botanicals together in one clinically studied integrated extract, rooted in tradition and validated by science. I'm excited to share its benefits with the health and wellness industry, and those looking for unique products."

Dr. Taz's endorsement adds to the growing momentum behind Fenavari's launch.

Fenavari is a proprietary integrated extract of fenugreek (Trigonella foenum-graecum) and shatavari (Asparagus racemosus), each providing complementary steroidal saponins that act through phytoestrogenic, adaptogenic, and antioxidant pathways involved in the menopausal transition. In a randomized, double-blind, placebo-controlled clinical study, Fenavari was shown to address seven key concerns tied to midlife hormonal changes—including fewer hot flashes and night sweats, healthy hormonal support, and support for sleep quality, mood, and sexual wellness—with some results in as little as 14 days. It was also found that 97% of health care professionals who treat menopausal women said they would recommend Fenavari to their patients—making it the No. 1 doctor-recommended botanical ingredient among respondents in a recent survey†.

"Fenavari's launch is backed by a rigorous clinical program that has shown it to be both effective and safe. Moreover, what makes Fenavari unique is that it's not just a blend of shatavari and fenugreek. Our proprietary Integrated Actives technology brings them together in a way that delivers a more efficacious product than either botanical on its own—or from simply blending the two," said Abhijeet Morde, Vice President, Early Discovery & Translation Science at OmniActive. "As competition in this category intensifies, brands need ingredients that can back their claims with real clinical data, and that's exactly what Fenavari delivers."

As part of its official unveiling, Fenavari will be featured alongside OmniActive's other leading ingredients at SupplySide Global (booth #5273), October 28–30 in Las Vegas. At the show, Kratika Gupta, OmniActive's Chief Strategy and Marketing Officer, will speak on the Supplement Solutions Stage as part of the "Women's wellness matures: Frontiers in solutions for perimenopause, menopause, and postmenopause" panel, which brings together experts to address the growing demand for clinically backed women's health solutions.

To learn more about Fenavari, visit: www.omniactives.com/fenavari-doc-recommended.

About OmniActive Health Technologies
Established in 2005, OmniActive Health Technologies is committed to leading the consumer wellness industry through innovative science and natural ingredients. The company delivers science-backed, IP-protected Specialty Actives and an extensive portfolio of Standard Actives for global customers in the dietary supplements, functional foods, and beverage markets. Offices are located in Mumbai, India; Bridgewater, New Jersey; and Amsterdam, Netherlands.

Media Contact:
Meredith Kish
[email protected]
973.202.4034

†Based on a survey of physicians who treat menopausal women, conducted by the Natural Marketing Institute on behalf of OmniActive. This reflects respondents' stated likelihood of recommending the ingredient when presented among botanical options.

SOURCE OmniActive Health Technologies